Pemphigus Vulgaris – Epidemiology – Middle East & Africa
Clarivate Epidemiology’s coverage of PV comprises epidemiological estimates of key patient populations in the major Middle East & Africa pharmaceutical markets (Egypt, Nigeria, Saudi Arabia, and South Africa). We report both the diagnosed incidence and prevalence of PV for each country, as well as annualized case counts projected to the national population.
Clarivate Epidemiology’s forecast will answer the following questions:
- How many people in each of the major Middle East & Africa pharmaceutical markets have been formally diagnosed with PV; how many are newly diagnosed each year?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of PV over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts three patient populations, as follows:
- Diagnosed incident cases.
- Diagnosed prevalent cases.
- Diagnosed incident cases by severity.
Note: Coverage may vary by country.
Table of contents
- Pemphigus Vulgaris - Epidemiology - Middle East & Africa
- Introduction
- Key Findings
- Diagnosed Prevalence of Pemphigus Vulgaris per 100,000 People in 2021 and 2031
- Diagnosed Prevalence of Pemphigus Vulgaris per 100,000 People in 2021 and 2031
- Relative Sizes of the Contributing Factors to the Trend in Diagnosed Prevalent Cases of Pemphigus Vulgaris over the Next 10 Years
- Relative Sizes of the Contributing Factors to the Trend in Diagnosed Prevalent Cases of Pemphigus Vulgaris over the Next 10 Years
- Epidemiology Data
- Methods
- Reference Materials
- Introduction
Utsav Patel, M.P.H., is an associate epidemiologist at Clarivate. His areas of interest are cardiovascular diseases and cancer epidemiology. Previously, he worked as a graduate research assistant at City University of New York, where he conducted multi-omics investigations into cancer study funded by the National Institutes of Health. He obtained his M.P.H. in epidemiology and biostatistics from City University of New York.
Thomas J. Arndt, M.P.H., C.P.H., is a senior epidemiologist at Clarivate. He earned his master’s degree in public health at the University of Florida, where he conducted an internship developing a clinical model for noninvasively screening for nonalcoholic steatohepatitis (NASH). He also holds a B.S. in microbiology and cell science and a B.A. in Spanish, both from the University of Florida. While studying at the University of Florida, Mr. Arndt worked in two physiology-based research labs focusing on maternal and fetal stresses during pregnancy and parturition.